Trial · NCT03449134
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Model-Based Geometric Mean Ratio (GMR) of 24-hour Objective Coughs Per Hour (Week 12/Baseline) | Placebo | 0.47 | 95% Confidence Interval 0.41 to 0.54 | ratio | |
| Model-Based Geometric Mean Ratio (GMR) of 24-hour Objective Coughs Per Hour (Week 12/Baseline) | Gefapixant 15 mg BID | 0.48 | 95% Confidence Interval 0.41 to 0.55 | ratio | |
| Model-Based Geometric Mean Ratio (GMR) of 24-hour Objective Coughs Per Hour (Week 12/Baseline) | Gefapixant 45 mg BID | 0.38 | 95% Confidence Interval 0.33 to 0.44 | ratio | |
| Number of Participants Experiencing At Least One Adverse Event (AE) During Treatment and Follow-up | Placebo | 184 | Participants | ||
| Number of Participants Experiencing At Least One Adverse Event (AE) During Treatment and Follow-up | Gefapixant 15 mg BID | 186 | Participants | ||
| Number of Participants Experiencing At Least One Adverse Event (AE) During Treatment and Follow-up | Gefapixant 45 mg BID | 208 | Participants | ||
| Number of Participants Who Discontinued Treatment Due to AEs | Placebo | 14 | Participants | ||
| Number of Participants Who Discontinued Treatment Due to AEs | Gefapixant 15 mg BID | 15 | Participants | ||
| Number of Participants Who Discontinued Treatment Due to AEs | Gefapixant 45 mg BID | 51 | Participants | ||
| Model-Based Geometric Mean Ratio (GMR) of Awake Objective Coughs Per Hour (Week 12/Baseline) | Placebo | 0.46 | 95% Confidence Interval 0.40 to 0.53 | ratio | |
| Model-Based Geometric Mean Ratio (GMR) of Awake Objective Coughs Per Hour (Week 12/Baseline) | Gefapixant 15 mg BID | 0.47 | 95% Confidence Interval 0.41 to 0.55 | ratio | |
| Model-Based Geometric Mean Ratio (GMR) of Awake Objective Coughs Per Hour (Week 12/Baseline) | Gefapixant 45 mg BID | 0.38 | 95% Confidence Interval 0.33 to 0.44 | ratio | |
| Percentage of Participants (Model-Based) With a ≤ -30% Change From Baseline in 24-hour Objective Coughs Per Hour at Week 12 | Placebo | 65.9 | Percentage of Participants | ||
| Percentage of Participants (Model-Based) With a ≤ -30% Change From Baseline in 24-hour Objective Coughs Per Hour at Week 12 | Gefapixant 15 mg BID | 66.2 | Percentage of Participants | ||
| Percentage of Participants (Model-Based) With a ≤ -30% Change From Baseline in 24-hour Objective Coughs Per Hour at Week 12 | Gefapixant 45 mg BID | 69.9 | Percentage of Participants | ||
| Percentage of Participants (Model-Based) With a ≤ -1.3-point Change From Baseline in Mean Weekly Cough Severity Diary (CSD) Total Score at Week 12 | Placebo | 52.4 | Percentage of Participants | ||
| Percentage of Participants (Model-Based) With a ≤ -1.3-point Change From Baseline in Mean Weekly Cough Severity Diary (CSD) Total Score at Week 12 | Gefapixant 15 mg BID | 62.1 | Percentage of Participants | ||
| Percentage of Participants (Model-Based) With a ≤ -1.3-point Change From Baseline in Mean Weekly Cough Severity Diary (CSD) Total Score at Week 12 | Gefapixant 45 mg BID | 60.5 | Percentage of Participants | ||
| Percentage of Participants (Model-Based) With a ≤ -2.7-point Change From Baseline in Mean Weekly CSD Total Score at Week 12 | Placebo | 28.6 | Percentage of Participants | ||
| Percentage of Participants (Model-Based) With a ≤ -2.7-point Change From Baseline in Mean Weekly CSD Total Score at Week 12 | Gefapixant 15 mg BID | 37.9 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03449134/results